SACD19-101 is under clinical development by Sian Wuhan Medical Technology and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III drugs for Follicular Lymphoma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SACD19-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SACD19-101 is under development for the treatment of relapsed or refractory CD19 positive B cell malignancies including indolent B-cell lymphoma such as B-cell acute lymphocytic leukemia (B-cell acute lymphoblastic leukemia), follicular lymphoma, aggressive B-cell lymphoma such as diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma. It is administered as an infusion. The therapeutic candidate constitutes lentivirally transduced autologous CAR T cells genetically modified to target CD19. It was also under development for the treatment of marginal zone B-cell lymphoma, waldenstrom macroglobulinemia, B-cell acute lymphocytic leukemia, lymphoplasmacytic lymphoma and chronic lymphocytic leukemia.
For a complete picture of SACD19-101’s drug-specific PTSR and LoA scores, buy the report here.